2023
The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease
DeBroff J, Omer N, Cohen B, Giladi N, Kestenbaum M, Shirvan J, Cedarbaum J, Gana‐Weisz M, Goldstein O, Orr‐Urtreger A, Mirelman A, Thaler A. The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease. Movement Disorders Clinical Practice 2023, 10: 606-616. PMID: 37070047, PMCID: PMC10105114, DOI: 10.1002/mdc3.13722.Peer-Reviewed Original ResearchDiagnosis of PDParkinson's diseaseMood-related disordersTime of assessmentMood disordersIdiopathic PDNon-motor comorbiditiesNon-motor featuresIdiopathic Parkinson's diseaseNon-motor phenotypeFrequency of depressionMood related disordersState of depressionPD patientsSuch medicationsWorse motorGenetic statusMedicationsProdromal stageRelated disordersGBA genePD diagnosisDiseaseDiagnosisDisorders
2021
Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders
Schulz I, Kruse N, Gera R, Kremer T, Cedarbaum J, Barbour R, Zago W, Schade S, Otte B, Bartl M, Hutten S, Trenkwalder C, Mollenhauer B. Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders. Movement Disorders 2021, 36: 2874-2887. PMID: 34363416, DOI: 10.1002/mds.28738.Peer-Reviewed Original ResearchConceptsGlial fibrillary acidic proteinCerebrospinal fluidChitinase-3-like protein 1Calcium-binding protein BUbiquitin C-terminal hydrolase L1Myeloid cells 2Neurofilament light chainObjective diagnostic biomarkersFibrillary acidic proteinNeurofilament heavy chainDiagnostic biomarker candidatesDiagnostic biomarkersClinical diagnosisTau proteinPhosphorylated aSynNeurodegenerative disordersAcidic proteinCells 2Α-synucleinBiomarker candidatesProtein 1Candidate markersAvailable kitsDisordersLight chain
2015
Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology
Cedarbaum JM, Stephenson D, Rudick R, Carrillo MC, Stebbins G, Kerr D, Heemskerk J, Galpern WR, Kaufmann P, Cella D, Isaac M, Walton MK. Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology. Neurotherapeutics 2015, 12: 151-169. PMID: 25384682, PMCID: PMC4322066, DOI: 10.1007/s13311-014-0310-1.Peer-Reviewed Original ResearchConceptsOutcome measuresNeurological disordersDisease-specific outcome measuresClinical trial measuresAssessment of dysfunctionAutonomic system functionMotor functionNervous systemRelated disordersDisordersDisease areasAmerican SocietyDrug developmentDysfunctionTrial measuresTerms of cognitionNeurologyAssessment developmentSystem functionAnnual MeetingNeurologistsSymptomsNeurotherapeutics